TIL Therapy for Cervical Cancer: Clinical Trials & Research Status

Current Status: Investigational, Not Approved

While TIL therapy has received FDA approval for advanced melanoma (Amtagvi/lifileucel, February 2024), its use in cervical cancer remains strictly investigational. This means:

• TIL therapy is not available as a standard treatment for cervical cancer
• Access is limited to patients enrolled in registered clinical trials
• The safety and efficacy profile in cervical cancer is still being established
• Regulatory approval may or may not be granted in the future, depending on trial results

Why Is TIL Therapy Being Studied in Cervical Cancer?

Cervical cancer presents unique biological characteristics that make it a compelling target for TIL therapy research:

HPV-Driven Immunogenicity

Most cervical cancers are caused by persistent infection with high-risk human papillomavirus (HPV). This viral etiology means that cervical cancer cells often express viral antigens (HPV E6 and E7 proteins) that can be recognized by the immune system. This makes cervical cancer potentially more "visible" to immune cells compared to some other solid tumors.

Tumor-Infiltrating Lymphocytes

Studies have shown that cervical cancers often contain significant numbers of tumor-infiltrating lymphocytes (TILs) — immune cells that have naturally migrated into the tumor. The presence of these cells suggests that the immune system is already attempting to fight the cancer, but may be suppressed or exhausted.

Unmet Medical Need

Advanced or recurrent cervical cancer that has progressed after standard treatments (surgery, chemotherapy, radiation, immunotherapy) has limited treatment options. TIL therapy represents a potential new approach for these heavily pre-treated patients.

Active Clinical Trials: LN-145 and Beyond

Several clinical trials are evaluating TIL therapy in cervical cancer, with the most advanced being the LN-145 program:

LN-145 (Iovance Biotherapeutics) — innovaTIL-04 Trial

LN-145 is an investigational TIL therapy product specifically developed for cervical cancer. The pivotal trial is C-145-04 (also known as innovaTIL-04, ClinicalTrials.gov identifier NCT03108495). Key features include:

• Trial Design: Phase 2 study evaluating LN-145 in patients with persistent, recurrent, or metastatic cervical cancer who have progressed on at least one line of chemotherapy
• Preliminary Results: Early cohort data has shown an objective response rate (ORR) of approximately 40-44% in heavily pre-treated populations, with some durable responses observed
• Safety Profile: Generally consistent with the known safety profile of TIL therapy (lymphodepletion effects, IL-2 toxicity), though cervical cancer-specific data is still being collected

Other Investigational TIL Products

Additional academic and industry-sponsored trials are evaluating TIL therapy in cervical cancer, including:

• Combination approaches with checkpoint inhibitors (e.g., pembrolizumab)
• Trials in earlier lines of therapy
• Studies exploring biomarkers to predict response

Key Differences: Cervical Cancer vs. Approved Melanoma Indication

Understanding the differences between TIL therapy in cervical cancer (investigational) and melanoma (approved) is critical for setting realistic expectations:

Aspect	Cervical Cancer Investigational	Melanoma Approved
Regulatory Status	Not FDA-approved; clinical trials only	FDA-approved (Amtagvi, Feb 2024)
Available Product	LN-145 (investigational)	Lifileucel (Amtagvi)
Clinical Evidence	Phase 2 trials (C-145-04); preliminary data	Phase 2 C-144-01 trial; FDA-reviewed
Response Rate	~40-44% (preliminary, early cohort data)	~31% (C-144-01 trial)
Long-Term Data	Limited; follow-up ongoing	Available; durable responses observed
Access	Clinical trial enrollment only	Commercially available at certified centers
Insurance Coverage	Varies; trial-specific	Generally covered for eligible patients

Eligibility Considerations for Clinical Trials

Clinical trials for TIL therapy in cervical cancer typically have strict eligibility criteria. While specific requirements vary by trial, common considerations include:

Disease Status

• Persistent, recurrent, or metastatic cervical cancer
• Progression after at least one line of chemotherapy (some trials require more)
• Measurable disease on imaging (for response assessment)

Prior Treatments

• Most trials require failure of standard therapies (chemotherapy, often immunotherapy)
• Some trials exclude patients who have received prior TIL therapy or certain experimental treatments

Surgical Candidacy

• Ability to undergo tumor biopsy or resection for TIL harvest
• Accessible tumor lesion (cervical, pelvic, or metastatic site)

Organ Function & Performance Status

• Adequate bone marrow, liver, kidney, and lung function
• ECOG performance status 0-1 (generally)
• No active infections or uncontrolled medical conditions

HPV Status

• Some trials require confirmation of HPV-positive tumor (though not all)

Treatment Process in Clinical Trials

The TIL therapy process in clinical trials is generally similar to the approved melanoma protocol, though with some variations:

1. Screening & Enrollment: Comprehensive evaluation to confirm trial eligibility, including imaging, biopsy review, and organ function tests
2. Tumor Harvest: Surgical biopsy or resection of accessible tumor tissue for TIL extraction
3. Manufacturing: TILs are isolated and expanded in a specialized laboratory (typically 4-6 weeks)
4. Lymphodepletion: Chemotherapy (cyclophosphamide + fludarabine) to suppress existing immune system
5. TIL Infusion: Intravenous infusion of expanded TILs
6. IL-2 Administration: High-dose IL-2 to support TIL survival (with intensive monitoring)
7. Follow-Up: Close monitoring for response, side effects, and long-term outcomes

Note: Clinical trials may include additional protocol-specific procedures, assessments, or follow-up requirements beyond the standard TIL therapy process.

Side Effects: What to Expect

The side effect profile of TIL therapy in cervical cancer is expected to be similar to that observed in melanoma, though cervical cancer-specific data is still limited. Key side effects include:

• Lymphodepletion Effects: Low blood counts, infection risk, fatigue
• IL-2 Toxicity: Capillary leak syndrome, low blood pressure, organ dysfunction (requires ICU monitoring)
• Surgical Risks: Pain, infection, bleeding at biopsy/resection site
• Immune-Related Effects: Potential for autoimmune reactions (thyroid, skin, GI tract)

For detailed information on TIL therapy side effects, see our comprehensive side effects guide →

Unspoken Questions: What Patients Really Want to Know

"Is TIL therapy a cure for cervical cancer?"

No. TIL therapy is not a guaranteed cure. In clinical trials, some patients have achieved objective responses (tumor shrinkage), and a subset may have durable responses. However, long-term cure rates are not yet established. TIL therapy should be viewed as a potential treatment option, not a definitive cure.

"What if I'm not eligible for a clinical trial?"

If you do not meet the eligibility criteria for a TIL therapy trial, your oncologist can discuss other treatment options, which may include:

• Other immunotherapy approaches (checkpoint inhibitors, antibody-drug conjugates)
• Targeted therapies (if specific mutations are present)
• Clinical trials of other investigational treatments
• Palliative care to manage symptoms and improve quality of life

"How do I find a clinical trial?"

Your oncologist is the best resource for identifying appropriate clinical trials. Additionally, you can search for active trials on ClinicalTrials.gov or contact major cancer centers directly. CancerCareE can also help you understand trial options and connect you with appropriate resources.

"Will insurance cover TIL therapy in a clinical trial?"

Insurance coverage for investigational TIL therapy varies widely. Some trials cover the cost of the investigational product and trial-specific procedures, while patients may be responsible for standard care costs (hospitalization, imaging, etc.). It is essential to discuss financial considerations with the trial team and your insurance provider before enrollment.

"What are the risks of participating in a clinical trial?"

Clinical trials involve unknown risks, as the treatment is still being studied. Potential risks include:

• Side effects that are not yet fully understood
• The possibility that TIL therapy may not work for your cancer
• Time commitment for trial visits and follow-up
• Financial costs not covered by insurance or the trial

However, clinical trials also offer potential benefits, including access to novel therapies, close monitoring by expert teams, and the opportunity to contribute to medical research.

Global Access & Clinical Trial Availability

TIL therapy clinical trials for cervical cancer are primarily being conducted in the United States, with some trials in Europe and other regions. Key considerations for international patients include:

• Travel Requirements: Patients typically need to travel to the trial site for screening, treatment, and follow-up visits
• Visa & Logistics: International patients must secure appropriate visas and arrange accommodation near the trial site
• Language & Communication: Trials are typically conducted in the local language; translation services may be available
• Follow-Up Care: Patients must be willing to return to the trial site for scheduled follow-up visits or arrange local follow-up with trial team approval

What Records Will the Trial Team Need?

If you are interested in participating in a TIL therapy clinical trial for cervical cancer, the trial team will typically require:

• Pathology Reports: Confirmation of cervical cancer diagnosis, including histology, grade, and HPV status (if available)
• Treatment History: Detailed records of all prior treatments (surgery, chemotherapy, radiation, immunotherapy), including dates, dosages, and response
• Imaging: Recent CT, PET/CT, or MRI scans to assess current disease status
• Laboratory Results: Recent blood work (CBC, metabolic panel, coagulation studies)
• Performance Status: Documentation of your current activity level and overall health

Having these records organized and up-to-date can expedite the screening process.

Questions to Ask Your Oncologist or Trial Team

1. Am I eligible for any active TIL therapy clinical trials for cervical cancer?
2. What are the potential benefits and risks of participating in this trial?
3. What is the trial's primary endpoint (e.g., response rate, survival)?
4. What are the trial's specific eligibility criteria, and do I meet them?
5. What costs will be covered by the trial, and what will I be responsible for?
6. How long will the trial participation require, and what is the follow-up schedule?
7. What happens if my cancer progresses during the trial?
8. Are there alternative treatments or clinical trials I should consider?

Related Resources

Frequently Asked Questions